Michael Alfieri
Aldeyra TherapeuticsAbout Michael Alfieri
Michael Alfieri, age 60, serves as Principal Financial Officer and Principal Accounting Officer of Aldeyra Therapeutics (ALDX) effective August 31, 2024, providing services via Danforth Global, Inc. under a consulting arrangement; he holds B.S. and M.S. degrees from Bentley University and previously held senior finance roles at Genocea Biosciences, Radius Health, and Merrimack Pharmaceuticals . As a contractor, his 2024 compensation consisted of fees paid to Danforth with no equity grants or bonus eligibility, and he held no Aldeyra shares as of April 14, 2025, indicating limited direct equity alignment . Company performance context: Aldeyra’s TSR (value of initial fixed $100) was $174.00 (2022), $87.75 (2023), and $124.75 (2024); net income was $(62,025)k (2022), $(37,543)k (2023), and $(55,851)k (2024) .
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| TSR – Value of $100 Investment | $174.00 | $87.75 | $124.75 |
| Net Income ($USD Thousands) | ($62,025) | ($37,543) | ($55,851) |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Danforth Global, Inc. | Finance Consultant to life sciences; provides PFO/PAO services to ALDX | Sep 2019–present | Strategic and operational finance leadership for public/private biotech |
| Genocea Biosciences, Inc. | Vice President, Finance; Principal Financial Officer | Apr 2018–Mar 2019 | Public company finance leadership and SEC reporting |
| Radius Health, Inc. | Vice President, Finance | Jan 2017–Apr 2018 | Commercial-stage biopharma finance leadership |
| Merrimack Pharmaceuticals, Inc. | Corporate Controller | 2014–2017 | Corporate controllership, reporting, and controls in biopharma |
| Education | B.S., M.S. Bentley University | — | Formal training in accounting/finance |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| — | None disclosed in SEC filings | — | No public company directorships or external board roles disclosed |
Fixed Compensation
| Year | Base Salary | Fees to Danforth (Contractor) | Target Bonus % | Actual Bonus Paid | Notes |
|---|---|---|---|---|---|
| 2024 | N/A (contractor) | $111,650 | N/A (contractor) | N/A | Under Master Services Agreement with Danforth; hourly rate arrangement |
Performance Compensation
| Component | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Annual Cash Bonus (2024) | Corporate performance goals | — | Not eligible | Not eligible | — | — |
| Notes | Mr. Alfieri was not eligible for a 2024 bonus due to his contractor status under the Danforth agreement . |
Equity Ownership & Alignment
| Holder | Shares Beneficially Owned | % of Outstanding | Vested vs. Unvested | Options (Exercisable/Unexercisable) | Pledged/Hedged |
|---|---|---|---|---|---|
| Michael Alfieri | 0 | <1% | None (no RSUs/PSUs) | None | Company policy prohibits hedging; pledging requires prior clearance |
- Stock ownership guidelines: Not disclosed for executives; directors have an option-based program; executive guidelines not specified .
- Section 16 compliance: Company indicates 2024 compliance for officers; one late Form 4 related to a director, not to Alfieri .
Employment Terms
| Term | Details |
|---|---|
| Title/Start Date | Principal Financial Officer and Principal Accounting Officer; effective August 31, 2024 |
| Engagement | Independent contractor via Danforth Master Services Agreement (Aug 5, 2024); hourly cash compensation |
| Termination | With cause: 30 days’ written notice; without cause: 60 days’ written notice (by either Aldeyra or Danforth) |
| Severance | No individual severance terms disclosed for Alfieri; severance provisions in proxy apply to certain employees (e.g., CEO, CDO), not contractors |
| Change-of-Control | CIC Plan accelerates awards for eligible employees upon double-trigger; not applicable to Alfieri given no outstanding equity and contractor status |
| Clawback | Nasdaq-compliant clawback policy for executive officers in case of financial restatement |
| Trading Restrictions | Hedging prohibited; pledging requires prior clearance under Insider Trading Policy |
Investment Implications
- Alignment: As a contractor with no equity holdings and no 2024 bonus eligibility, Alfieri’s direct pay-for-performance linkage and equity alignment are limited; beneficial ownership is 0 shares and no options as of April 14, 2025 .
- Retention risk: Engagement can be terminated without cause on 60 days’ notice by either party, suggesting flexibility but also potential turnover risk typical of consulting arrangements .
- Selling pressure: With no equity ownership or awards outstanding, near-term insider selling pressure from Alfieri is negligible .
- Governance and controls: He is covered by the company’s clawback and insider trading policies, supporting discipline on financial reporting and limiting hedging/pledging risks .
- Company performance context: Aldeyra’s 2024 net loss of $(55,851)k and TSR recovery to $124.75 (from $87.75 in 2023) frame the operating backdrop for finance leadership priorities under Alfieri’s tenure .